580 related articles for article (PubMed ID: 28295923)
1. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
2. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
[TBL] [Abstract][Full Text] [Related]
3. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
5. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
7. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
[TBL] [Abstract][Full Text] [Related]
8. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
Kotani K; Enomoto M; Uchida-Kobayashi S; Tamori A; Yukawa-Muto Y; Odagiri N; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Kageyama K; Yamamoto A; Yoshida A; Higashiyama S; Kawabe J; Kawada N
J Gastroenterol; 2023 Apr; 58(4):394-404. PubMed ID: 36729172
[TBL] [Abstract][Full Text] [Related]
9. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Mandorfer M; Kozbial K; Freissmuth C; Schwabl P; Stättermayer AF; Reiberger T; Beinhardt S; Schwarzer R; Trauner M; Ferlitsch A; Hofer H; Peck-Radosavljevic M; Ferenci P
Aliment Pharmacol Ther; 2015 Sep; 42(6):707-18. PubMed ID: 26179884
[TBL] [Abstract][Full Text] [Related]
10. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
Rincon D; Ripoll C; Lo Iacono O; Salcedo M; Catalina MV; Alvarez E; Nuñez O; Matilla AM; Clemente G; Bañares R
Am J Gastroenterol; 2006 Oct; 101(10):2269-74. PubMed ID: 17032192
[TBL] [Abstract][Full Text] [Related]
12. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
[TBL] [Abstract][Full Text] [Related]
13. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
[TBL] [Abstract][Full Text] [Related]
14. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
15. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
[TBL] [Abstract][Full Text] [Related]
16. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of 833 times measured hepatic venous pressure gradient].
Zhang MY; Wang GC; Huang GJ; Feng H; Wang LF; Zhang JY; Shi YJ; Zhang CQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):266-270. PubMed ID: 29996337
[No Abstract] [Full Text] [Related]
18. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
[TBL] [Abstract][Full Text] [Related]
19. [Hepatic cein catheterisation - selected assessment aspects].
Petrtýl J; Brůha R; Urbánek P; Mareček Z; Kaláb M
Vnitr Lek; 2013 Jul; 59(7):587-90. PubMed ID: 23909264
[TBL] [Abstract][Full Text] [Related]
20. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg.
Jindal A; Bhardwaj A; Kumar G; Sarin SK
Am J Gastroenterol; 2020 Oct; 115(10):1624-1633. PubMed ID: 32453061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
